Newron Pharmaceuticals Ratios and Metrics

Market cap in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	216	174	88	28	29	38	Upgrade
Market Cap Growth	41.83%	97.16%	219.36%	-4.32%	-24.65%	-66.14%	Upgrade
Enterprise Value	225	209	118	44	34	23	Upgrade
Last Close Price	10.82	8.95	4.95	1.55	1.62	2.15	Upgrade
PE Ratio	9.73	11.72	-	-	-	-	Upgrade
Forward PE	-	10.63	-	7.84	-	-	Upgrade
PS Ratio	3.86	3.61	10.48	4.59	4.84	6.74	Upgrade
PB Ratio	146.17	127.32	-3.17	-1.99	8.98	2.06	Upgrade
P/TBV Ratio	146.27	127.32	-	-	8.98	2.06	Upgrade
EV/Sales Ratio	4.02	4.34	13.95	7.26	5.77	4.13	Upgrade
EV/EBITDA Ratio	6.80	8.52	-	-	-	-	Upgrade
EV/EBIT Ratio	6.84	8.53	-	-	-	-	Upgrade
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53	Upgrade
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-	Upgrade
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09	Upgrade
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50	Upgrade
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50	Upgrade
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%	Upgrade
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%	Upgrade
Return on Capital (ROIC)	60.97%	46.45%	-28.99%	-21.37%	-17.21%	-23.21%	Upgrade
Return on Capital Employed (ROCE)	165.20%	64.80%	-	-	-	-	Upgrade
Earnings Yield	10.95%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%	Upgrade
FCF Yield	10.61%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%	Upgrade
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.